HIV replicates by hijacking your immune cells and turning them into virus-producing factories. The entire process, from the moment the virus latches onto a cell to the release of new viral copies, takes roughly 24 hours and follows seven distinct stages. In someone with an untreated infection, this cycle produces an estimated 10 billion new viral particles every single day.
Understanding how this works isn’t just academic. Every major class of HIV medication is designed to block a specific step in this cycle, which is why knowing the stages helps explain how treatment works and why the virus is so difficult to eliminate.
The Target: CD4 Immune Cells
HIV primarily infects CD4+ T cells, a type of white blood cell that coordinates your immune response. But these aren’t the only targets. Macrophages (immune cells stationed in tissues throughout the body), dendritic cells, and even specialized cells in the brain, liver, and bone are all vulnerable. They share a common trait: they all carry the CD4 receptor on their surface, which is the molecule HIV uses as its entry point.
This broad range of targets matters because some of these cells, particularly macrophages and brain-resident immune cells called microglia, can harbor the virus for long periods. Even in people on effective treatment, latent HIV has been detected in monocytes (precursors to macrophages) in about half of those studied. These hidden reservoirs are a central reason HIV can’t be fully cured with current therapies.
Step 1: Binding and Fusion
The replication cycle begins when HIV encounters a CD4 cell. Proteins on the virus’s surface lock onto the CD4 receptor like a key fitting into a lock. But this first connection isn’t enough to get inside. The virus also needs to grab a second receptor, called a coreceptor, on the cell’s surface.
Two coreceptors matter most. CCR5 is the main one used by HIV strains that dominate early in infection, during the years a person may feel fine. CXCR4 is favored by more aggressive strains that tend to emerge later as the disease progresses toward AIDS. Once the virus binds both the CD4 receptor and a coreceptor, it fuses its outer envelope directly with the cell membrane and dumps its genetic contents inside.
Step 2: Reverse Transcription
This is the step that makes HIV unusual. Most organisms store their genetic instructions as DNA. HIV carries its genome as RNA, a single-stranded molecule. To take over the cell, the virus needs to convert that RNA into DNA the cell can read. It does this using an enzyme it brought along called reverse transcriptase.
The process happens in the cell’s cytoplasm (the fluid-filled space outside the nucleus). Reverse transcriptase uses a small piece of the host cell’s own molecular machinery as a starting point, then builds a DNA copy of the viral RNA strand. As it works, a second function of the same enzyme chews up the original RNA, and then a complementary DNA strand is constructed. The end result is a complete double-stranded DNA version of the virus’s genome, capped on both ends with identical sequences that will help it slot into the host’s chromosomes.
Here’s the critical detail: reverse transcriptase is sloppy. It makes roughly one error for every 10,000 to 100,000 building blocks it copies. That sounds small, but with billions of new viruses produced daily, the math adds up fast. Each replication cycle introduces mutations, creating a swarm of genetically distinct variants. This built-in sloppiness is the engine behind drug resistance.
Step 3: Integration
Once the viral DNA is complete, it travels into the cell’s nucleus. There, a second viral enzyme called integrase cuts into the cell’s own chromosomes and inserts the viral DNA directly into them. The insertion is precise on the viral end, with the enzyme trimming two nucleotides from each end of the viral DNA before stitching it into the host genome with a characteristic five-base-pair duplication at the insertion site.
The integrated viral DNA is now called a provirus, and this is what makes HIV so persistent. The provirus becomes a permanent part of the cell’s genetic code. Every time the cell divides, it copies the viral DNA right along with its own. If the cell is long-lived or enters a resting state, the provirus can sit silently for years, invisible to the immune system and unaffected by medications that only target active replication.
Step 4: Replication and Assembly
When the host cell is activated, it reads the proviral DNA just as it would its own genes, producing long strands of messenger RNA. Some of these RNA strands serve as blueprints for building viral proteins. Others become the genetic material that will be packaged into new virus particles. The cell’s own protein-building machinery does all the work, assembling long chains of viral proteins called polyproteins.
These polyproteins and copies of the viral RNA genome migrate to the inner surface of the cell membrane, where they begin organizing into new, immature virus particles. At this stage the proteins are still fused together in long, nonfunctional chains. The particle that forms is not yet infectious.
Step 5: Budding and Maturation
The assembled immature particles push outward through the cell membrane, wrapping themselves in a piece of it as they exit. This process, called budding, typically begins around 18 hours after the initial infection of the cell. The virus doesn’t always kill the host cell immediately; some cells continue budding new particles for a time before dying.
The final transformation happens after the new particle has left the cell. A viral enzyme called protease activates and begins cutting the long polyprotein chains into their individual functional components: the structural proteins that form the virus’s core, the reverse transcriptase it will need to infect the next cell, and the integrase for inserting its DNA. This cutting has to happen in a specific order. If the sequence is disrupted, the virus forms an abnormal structure and loses its ability to infect new cells. Correct processing triggers a dramatic physical rearrangement, transforming the shapeless immature blob into a mature particle with a distinctive cone-shaped core. Only then is the virus infectious and ready to start the cycle again.
Why the Cycle Is So Hard to Stop
Two features of this replication cycle make HIV exceptionally difficult to control. The first is speed and volume. Ten billion new viruses per day means the viral population is constantly evolving. When antiretroviral drugs are present, any mutant that happens to resist those drugs has an enormous selective advantage. Drug-resistant strains can completely replace the original virus population within two to four weeks if treatment is incomplete or inconsistent.
The second feature is the provirus. Because integrated viral DNA is indistinguishable from the cell’s own genome, no current drug can remove it. Antiretroviral therapy can halt active replication, driving the amount of virus in the blood to undetectable levels, but the provirus remains in long-lived cells. If treatment stops, those cells can reactivate and restart the cycle.
How Medications Target Each Step
Modern HIV treatment uses combinations of drugs that block different stages of the replication cycle simultaneously, making it far harder for resistant mutants to survive.
- Entry and fusion inhibitors block the virus from binding to CD4 or its coreceptors, preventing the very first step.
- NRTIs (nucleoside reverse transcriptase inhibitors) mimic the building blocks of DNA. When reverse transcriptase grabs one and adds it to the growing chain, the chain can’t be extended any further, halting DNA synthesis.
- NNRTIs (non-nucleoside reverse transcriptase inhibitors) take a different approach. They bind directly to reverse transcriptase and warp its shape so it can no longer function.
- Integrase inhibitors block the integrase enzyme by interfering with the metal ions it needs to bind viral DNA to the host chromosome, preventing provirus formation.
- Protease inhibitors prevent the final maturation step, so new particles bud from the cell but remain immature and noninfectious.
By attacking the cycle at multiple points, combination therapy reduces viral production to near zero, preserves CD4 cell counts, and prevents progression to AIDS. The challenge that remains is the silent provirus, tucked inside resting cells, waiting.